LeMaitre Vascular has announced it will acquire the manufacturing and distribution rights to XenoSure from Neovasc, according to a news release.
XenoSure is a bovine pericardium patch used primarily for carotid and vascular reconstructions. LeMaitre Vascular, a provider of peripheral vascular devices and implants, will acquire the technology from Neovasc, a developer of vascular surgery tools and products, for $4.6M on Oct. 31.
LeMaitre Vascular has been the exclusive U.S. vascular distributor of XenoSure since January 2009, and owns the XenoSure trademark.
LeMaitre Vascular is headquartered in Burlington, Mass. Neovasc is headquartered in British Columbia, Canada.
Related Articles on Medical Technology:
DePuy Mitek Launches New Rotator Cuff Anchor
Covidien Unveils Cordless Ultrasonic Dissection Device and Stapling System
Abbott Launches Drug Eluting Bioresorbable Vascular Scaffold